EVOQ Therapeutics, Inc. (EVOQ), a biotechnology companyfocused on delivering transformative cures for those living with autoimmune diseases, todayannounced a Collaboration and License Agreement with Sanofi, an R&D driven, AI-poweredbiopharma company, committed to improving people's lives and delivering compelling growth. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
https://mma.prnewswire.com/media/1966883/EVOQ_Therapeutics_Logo.jpg
EVOQ's proprietary breakthrough NanoDisc technology restores the body's natural immunetolerance pathways and opens the door for a wide range of disease-specific, curative therapiesfor multiple autoimmune diseases like celiac disease, type 1 diabetes, MOG (myelinoligodendrocyte glycoprotein) antibody disease, rheumatoid arthritis and lupus. Currenttreatments do not address the root cause of autoimmune disease which is the breakdown and failure of the body's immune tolerance systems which results in the destruction of self-tissues.To cure autoimmune disease, immune tolerance must be restored.
“We are truly thrilled to be collaborating with Sanofi to advance our NanoDisc technology,” saidDavid Giljohann, Ph.D., Chief Executive Officer at EVOQ. Giljohann added, “Sanofi's know-howin autoimmune disease and leadership in immunology will bring clinical development expertiseand commercial presence thereby making Sanofi a highly credible and attractive partner for our technology, uniquely positioned to deliver breakthrough efficacy and convenience for patients.”Under the terms of the agreement, EVOQ and Sanofi will collaborate on research activities, Sanofi will be responsible for the development and the commercialization efforts worldwide. EVOQ is eligible to receive over $500 million in total in upfront, preclinical, development andsales milestones, as well as tiered royalties on product sales.
About EVOQ TherapeuticsEVOQ Therapeutics is focused on the discovery and development of drugs to treat patientsafflicted with autoimmune diseases. EVOQ's technology platform utilizes a proprietary syntheticHDL NanoDisc that has been optimized to deliver antigens and small molecules to restoreimmune tolerance. For more information, please visit www.evoqtherapeutics.com
EVOQ Therapeutics Contact:Trevor ThompsonIonic Advisorstrevor@ionicadvisors.com
https://edge.prnewswire.com/c/img/favicon.png?sn=NY99551&sd=2025-10-16
View original content to download multimedia:https://www.prnewswire.com/news-releases/evoq-therapeutics-announces-collaboration-and-license-agreement-with-sanofi-302585825.html
SOURCE EVOQ Therapeutics, Inc.
https://rt.newswire.ca/rt.gif?NewsItemId=NY99551&Transmission_Id=202510160600PR_NEWS_USPR_____NY99551&DateId=20251016